The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) is a huge mover today! About 847,051 shares traded hands. Keryx Biopharmaceuticals (NASDAQ:KERX) has declined 8.37% since April 4, 2016 and is downtrending. It has underperformed by 9.46% the S&P500.
The move comes after 5 months positive chart setup for the $465.47 million company. It was reported on Nov, 4 by Barchart.com. We have $11.82 PT which if reached, will make NASDAQ:KERX worth $754.06M more.
Keryx Biopharmaceuticals (NASDAQ:KERX) Ratings Coverage
Out of 14 analysts covering Keryx Biopharmaceuticals (NASDAQ:KERX), 6 rate it a “Buy”, 2 “Sell”, while 6 “Hold”. This means 43% are positive. Keryx Biopharmaceuticals has been the topic of 28 analyst reports since July 23, 2015 according to StockzIntelligence Inc. The rating was downgraded by FBR Capital to “Market Perform” on Tuesday, August 2. The stock of Keryx Biopharmaceuticals (NASDAQ:KERX) earned “Buy” rating by TH Capital on Thursday, July 23. Raymond James maintained the stock with “Outperform” rating in Tuesday, August 2 report. The rating was upgraded by Morgan Stanley to “Equal-Weight” on Monday, October 5. On Thursday, July 23 the stock rating was downgraded by Cowen & Co to “Market Perform”. The company was downgraded on Tuesday, August 2 by Brean Capital. On Friday, February 26 the stock rating was upgraded by Raymond James to “Outperform”. On Friday, August 28 the stock rating was upgraded by Zacks to “Sell”. The firm has “Mkt Perform” rating given on Tuesday, August 11 by FBR Capital. Stifel Nicolaus downgraded the stock to “Hold” rating in Tuesday, August 2 report.
According to Zacks Investment Research, “Keryx Biophamaceutical, Inc. uses data discovered through the mapping of the human genome to generate drug candidates that target the regulation of protein kinases. Protein kinases play a key role in the way cells communicate.”
Insitutional Activity: The institutional sentiment decreased to 0.49 in Q2 2016. Its down 1.00, from 1.49 in 2016Q1. The ratio worsened, as 29 funds sold all Keryx Biopharmaceuticals shares owned while 43 reduced positions. 12 funds bought stakes while 23 increased positions. They now own 64.01 million shares or 1.49% less from 64.98 million shares in 2016Q1.
Blackrock Grp Incorporated Limited has 47,429 shares for 0% of their US portfolio. Goldman Sachs Group Incorporated has invested 0% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX). Invesco reported 19,454 shares or 0% of all its holdings. Blackrock Fund Advisors holds 0% or 1.88 million shares in its portfolio. Abrams Mgmt L P has 1.98% invested in the company for 5.72 million shares. Pnc Services Grp Inc last reported 0% of its portfolio in the stock. Lmr Prns Llp accumulated 0.02% or 18,824 shares. Ameriprise Financial holds 0.01% of its portfolio in Keryx Biopharmaceuticals (NASDAQ:KERX) for 1.56 million shares. Victory Cap Mgmt, a Ohio-based fund reported 2,443 shares. Brandywine Mngmt Ltd Llc has 335,672 shares for 0.01% of their US portfolio. Alliancebernstein L P reported 161,040 shares or 0% of all its holdings. Fmr Ltd Liability last reported 3.17 million shares in the company. State Street accumulated 2.51 million shares or 0% of the stock. Barclays Public Limited Com last reported 38,837 shares in the company. Ladenburg Thalmann Incorporated holds 0% or 5,575 shares in its portfolio.
Insider Transactions: Since May 9, 2016, the stock had 0 insider buys, and 11 insider sales for $99,346 net activity. Holmes Scott A had sold 1,237 shares worth $5,492. Neylan John F. had sold 1,211 shares worth $5,716. Madison Greg sold 1,622 shares worth $6,845. Adams Brian sold $3,481 worth of stock.
More news for Keryx Biopharmaceuticals (NASDAQ:KERX) were recently published by: Globenewswire.com, which released: “Keryx Biopharmaceuticals to Webcast its Presentation at Stifel’s 2016 …” on November 03, 2016. Fool.com‘s article titled: “What’s Behind Keryx Biopharmaceuticals’ 28.6% Jump in September?” and published on October 09, 2016 is yet another important article.
KERX Company Profile
Keryx Biopharmaceuticals, Inc., incorporated on October 22, 1998, is a biopharmaceutical company. The Firm is focused on the development of products for the treatment of renal diseases. The Company’s product Auryxia (ferric citrate), also known as Riona in Japan and Fexeric in Europe, is an oral, absorbable iron compound, which is indicated for the control of serum phosphorus levels in patients with chronic kidney disease (CKD), on dialysis. The Firm operates through the products segment. Auryxia can bind to phosphate in the gastrointestinal tract and form non-absorbable complexes to reduce intestinal absorption and aid in the management of hyperphosphatemia in patients with CKD. The adverse events for Auryxia treated patients were gastrointestinal-related, including diarrhea, nausea, constipation, vomiting and cough.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.